Clinical trials: IDDM
Type 1 Diabetes, Continuous Glucose Monitoring
Research on Optimizing the Use of Technology With Education
Consistent use of continuous glucose monitors (CGM) has the potential to improve glycemic control and related type 1 diabetes (T1D) health outcomes, however young adolescents with T1D are the least likely age group to begin and…
- Conditions
- Type 1 Diabetes, Continuous Glucose Monitoring, Behavioral Intervention, Parent-Child Relations
- Trial name
- ROUTE-T1D (NCT05564481)
- Testing
- diabetes education and parent coaching support
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Children's National Research Institute
Diabetes Mellitus, Diabetes Mellitus, Type 1
Day and Night Closed-loop in Young People With Type 1 Diabetes
The main study objective is to determine whether 24/7 automated closed-loop glucose control combined with low glucose feature will improve glucose control as measured by HbA1c.
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 1, Glucose Metabolism Disorders, Endocrine System Diseases
- Trial name
- DAN05 (NCT02925299)
- Testing
- FlorenceM (US) and FlorenceX (UK), Insulin pump therapy
- Where
- 11 sites in United States, United Kingdom
- Volunteers
- 133 people
- Sponsor
- Jaeb Center for Health Research
Type 1 Diabetes
Efficacy Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Patients
The purpose of this study is to determine if DiaPep277 can effectively protect the internal production of insulin in patients newly diagnosed with type 1 diabetes, by stopping the immune destruction of insulin-producing…
- Trial name
- DIA-AID (NCT00615264)
- Testing
- DiaPep277
- Where
- 34 sites in Austria, Czechia and 9 more
- Volunteers
- 457 people
- Sponsor
- Andromeda Biotech Ltd.
Type 1 Diabetes
STEP: Social Support To Empower Parents
This RCT intervention provides parental social support (informational, affirmational, and emotional) using parent mentors (experienced in the management of the chronic illness) for mothers and fathers of young children newly…
- Trial name
- STEP (NCT00480493)
- Testing
- STEP
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Massachusetts, Worcester
Type 1 Diabetes
Effects of Acipimox on Insulin Action, Vascular Function, and Muscle Function in Type 1 Diabetes
Insulin resistance (IR) is an important contributor to increased cardiovascular disease risk in type 1 diabetes (T1D). Non-esterified fatty acid elevation is a significant contributor to IR in T1D and may be a target of…
- Trial name
- AcT1 (NCT01816165)
- Testing
- Acipimox
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Type 1 Diabetes Mellitus
Glycemic Stability of Insulin Aspart Versus Insulin Lispro in Insulin Pump Therapy
The purpose of this study is to determine: 1. whether there is a difference between insulin aspart and insulin lispro in continuous insulin pump therapy 2.
- Trial name
- NCT00428207
- Testing
- Insulin Aspart versus Insulin Lispro, Insulin Lispro versus Insulin Aspart
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Joslin Diabetes Center
Type 1 Diabetes
Four Way Crossover Closed Loop With Exercise Detection
Closed-loop systems are an emerging technology that automate hormone delivery. They are quickly paving the way to revolutionize the treatment of type 1 diabetes.
- Trial name
- NCT02862730
- Testing
- Artificial Pancreas Controller in Dual Hormone Mode, Subject's insulin pump, Artificial Pancreas Controller in Single Hormone Mode
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Oregon Health and Science University
Type 1 Diabetes
Insulin Pump to Multiple Daily Injection Transition Clinical Trial
This randomized controlled, two arms, investigator initiated, intervention study is aimed to examine an investigational approach in contrast to the clinical standard of 1:1 dose basal insulin conversion in an attempt to lower the…
- Trial name
- TRANSITION (NCT03987191)
- Testing
- Multiple daily ijnection using Insulin Degludec and Insulin Aspart
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- University of Colorado, Denver
Diabetes Mellitus, Type 2
Pharmacokinetics, Pharmacodynamics, and Safety of Alogliptin in Children, Adolescents and Adults With Type 2 Diabetes Mellitus
The purpose of this study is to determine the pharmacokinetic and safety profile of alogliptin in children, adolescents, and adults with type 2 diabetes mellitus.
- Trial name
- NCT00957268
- Testing
- Alogliptin
- Where
- 7 sites in United States
- Volunteers
- 46 people
- Sponsor
- Takeda
Type 1 Diabetes Mellitus
The Artificial Pancreas in Very Young Children With T1D
The suggested clinical trial is part of the KidsAP project funded by the European Commission's Horizon 2020 Framework Programme and JDRF.
- Trial name
- KidsAP02 (NCT03784027)
- Testing
- CamAPS FX, Sensor augmented therapy
- Where
- 8 sites in Austria, Germany and 2 more
- Volunteers
- 81 people
- Sponsor
- University of Cambridge
Type 1 Diabetes
Effects of Single Doses of Liraglutide and Dapagliflozin on Ketogenesis in Type 1 Diabetes
1. To compare levels of ketone bodies (beta-hydroxybutyrate and acetoacetate) in plasma and urine following a single dose treatment of either liraglutide 1.8mg, dapagliflozin 10mg or placebo in insulinopenic state. 2.
- Trial name
- 1974 (NCT02777073)
- Testing
- Victoza, Dapagliflozin 10mg Tab
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- University at Buffalo
Diabetes, Type 1
Safety and Efficacy of Technosphere® Insulin Inhalation Powder and Lantus® Compared to Humalog® and Lantus® Over 16-Weeks
The objective of this study is to demonstrate that TI® Inhalation Powder combined with Lantus® is as effective as Humalog® combined with Lantus® on HbA1c.
- Trial name
- NCT00700622
- Testing
- Technosphere Insulin, Insulin glargine, Insulin lispro
- Where
- 22 sites in United States, Brazil
- Volunteers
- 130 people
- Sponsor
- Mannkind Corporation
Diabetes Mellitus, Type 1
A Study of LY900014 (Lyumjev) Versus Insulin Lispro (Humalog) in Participants With Type 1 Diabetes
This study will be conducted in participants with type 1 diabetes mellitus on continuous subcutaneous insulin infusion (CSII) or pump therapy to evaluate the effect of LY900014 (Lyumjev) on blood sugar levels during exercise…
- Trial name
- NCT05262387
- Testing
- Lyumjev with 50% basal rate reduction, Humalog with 50% basal rate reduction, Humalog with 100% basal rate reduction
- Where
- Canada
- Volunteers
- 25 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes
Extended Bolus for Meals in a Closed-loop System
This study aims to evaluate whether the use of an extended bolus will improve glucose control with high-fat high protein meals using a closed-loop system.
- Trial name
- NCT05454891
- Testing
- Tandem t:slim X2 insulin pump: Extended bolus of insulin then standard bolus of insulin, Tandem t:slim X2 insulin pump: Standard bolus of insulin then extended bolus of insulin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, San Francisco
Type 1 Diabetes Mellitus
A Pilot Study of Moderate Hyperbilirubinemia in Type 1 Diabetes Mellitus
Specific Aim: To establish the feasibility of studying the change in endothelial function caused by induced moderate hyperbilirubinemia in type 1 diabetes.
- Trial name
- NCT01421355
- Testing
- Atazanavir
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Brigham and Women's Hospital
Diabetes Mellitus, Type 1
Control-IQ Observational (CLIO) Post-Approval Study
Post-approval 522 study designed to collect primarily safety data on the US FDA-cleared product, t:slim X2 insulin pump with Control-IQ technology (Control-IQ system).
- Trial name
- CLIO (NCT04503174)
- Testing
- t:slim X2 pump with Control-IQ technology
- Where
- United States
- Volunteers
- 3,157 people
- Sponsor
- Tandem Diabetes Care, Inc.
Diabetes Mellitus, Type 1
Investigating Re-Dosing With Otelixizumab in Adults With Newly-Diagnosed Type 1 Diabetes Mellitus
The purpose of this study to assess the safety and tolerability of re-dosing at 6 months with otelixizumab (given as an 8-day series of intravenous infusions) in adult subjects with newly diagnosed type 1 diabetes mellitus
- Trial name
- NCT01222078
- Testing
- otelixizumab
- Where
- 2 sites in France, Germany
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Diabetic Ketoacidosis, Type 1 Diabetes Mellitus
Early Glargine (Lantus) in DKA Management in Children With Type 1 Diabetes
A frequent complication in the management of diabetic ketoacidosis (DKA) in children with type 1 diabetes is rebound hyperglycemia (blood glucose over 180 mg/dL) which increases the risk of re-developing DKA and can lengthen the…
- Trial name
- NCT03107208
- Testing
- Glargine, Continuous Glucose Monitor (Abbott FreeStyle Libre Pro)
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Diabetes Mellitus, Type 1
A Study in Adults With Type 1 Diabetes
The purpose of this study is to compare the effectiveness and safety of LY2963016 versus Lantus when taken once daily in combination with insulin lispro before meals three times a day.
- Trial name
- ELEMENT 1 (NCT01421147)
- Testing
- LY2963016, Lantus, Insulin Lispro
- Where
- 52 sites in United States, Belgium and 7 more
- Volunteers
- 536 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1
A Study of Insulin Peglispro and Glargine on Fats in Participants With Type 1 Diabetes
This study has two parts. Each participant will receive a daily injection of insulin peglispro during one treatment period and a daily injection of insulin glargine during the other treatment period.
- Trial name
- NCT01771250
- Testing
- Insulin Peglispro, Insulin Glargine
- Where
- Denmark
- Volunteers
- 15 people
- Sponsor
- Eli Lilly and Company